The deal brings Exact Sciences' flagship screening test for colorectal cancer, Cologuard, under Abbott's umbrella.

Abbott (NYSE: ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026. The announcement follows receipt of all regulatory clearances necessary for ...

Abbott Laboratories (NYSE:ABT) is one of the Best Conservative Stocks to Buy Right Now. On March 23, the company announced that it had completed the acquisition of Exact Sciences. As a result of this, ...

Abbott (NYSE:ABT) announced today that it completed its acquisition of cancer diagnostics developer Exact Sciences.

Exact Sciences accounts for an estimated $6 billion to $7 billion of Wisconsin's gross domestic product – as much as roughly ...

Abbott (NYSE: ABT) announced today that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026.

Abbott closes $21B acquisition of Exact Sciences (EXAS) at $105/share. EXAS delisted from Nasdaq on March 23, 2026, becoming ...

Abbott expects to close its acquisition of Exact Sciences on Monday, the healthcare giant said. Madison-based Exact Sciences ...

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

News of an apparently impending sale to a strategic investor sent shares of Exact Sciences (NASDAQ: EXAS) skyward on Wednesday. The cancer diagnostics specialist's shares closed the day nearly 24% ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the ...